Signia Therapeutics
Lyon
About Signia Therapeutics
Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.5M
- Funding stage: Early Stage Venture
- Last round: Grant (Jan 2022)
- Website: signiatherapeutics.com
- Phone: (+33) 478771037
Industries & Categories
Medical
Social Profiles
Canonical: https://fsome.com/organization/signia-therapeutics-135235 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.